Home > Articles > Published articles > Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation |
Date: | 2016 |
Abstract: | Small cell lung cancer (SCLC) is the most aggressive type of lung cancer with high mortality. One of the MYC family genes, MYC, MYCL or MYCN, is amplified in ~20% of the SCLCs; therefore, MYC proteins are potential therapeutic targets in SCLC patients. We investigated the therapeutic impact of Omomyc, a MYC dominant negative, in a panel of SCLC cell lines. Strikingly, Omomyc suppressed the growth of all tested cell lines by inducing cell cycle arrest and/or apoptosis. Induction of G1 arrest by Omomyc was found to be dependent on the activation of CDKN1A, in part, through the TP73 pathway. Our results strongly indicate that SCLC cells carrying amplification of MYC, MYCL or MYCN are addicted to MYC function, suggesting that MYC targeting would be an efficient therapeutic option for SCLC patients. |
Grants: | Instituto de Salud Carlos III II11-00014 Instituto de Salud Carlos III PI13-00849 Instituto de Salud Carlos III PI12-00511 Instituto de Salud Carlos III PI13-01705 European Commission 617473 |
Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Language: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Subject: | Small cell lung cancer ; MYC ; CDKN1A ; MYCL ; SCLC |
Published in: | Oncotarget, Vol. 7, Num. 21 (May 2016) , p. 31014-31028, ISSN 1949-2553 |
15 p, 7.1 MB |